Scholarlink

Purpose of review <p> The goal of this review is to consolidate the current understanding of cancer treatment-related bladder dysfunction and lower urinary tract symptoms.</p> Recent findings <p> Many cancer treatments are associated with irritative lower urinary tract symptoms. Chemotherapies can result in a hemorrhagic cystitis that can be difficult to manage. Common therapies for hemorrhagic cystitis include hyperbaric oxygen therapy, clot evacuation, fulguration, and intravesical instillation of astringent agents. Among breast cancer patients, some of those managed with endocrine therapies, such as selective estrogen receptor modulators and aromatase inhibitors, develop irritative voiding symptoms secondary to decreased estrogen stores. Immunotherapy-related adverse events regarding the bladder are rare and have only been described in case reports. These commonly include dysuria, hematuria, and urinary frequency. Lastly, in the setting of non-muscle invasive bladder cancer, intravesical therapies have been utilized in intermediate and high-risk disease. These intravesical therapies cause irritative urinary symptoms such as urgency, frequency, dysuria, and even urge incontinence. These side effects can lead to poor compliance which can lead to progression of disease.</p> Summary <p> Systemic and local intravesical treatments each contribute to the development and persistence of bothersome symptoms such as urgency, frequency, dysuria, and hematuria. Further studies looking at the implications of systemic and intravesical therapy-related bladder dysfunction during treatment and cancer survivorship could assist with the counseling and management of patients’ expectations, informing therapy selection during a shared-decision making process.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Irritative Voiding Symptoms and Bladder Dysfunction in the Setting of Intravesical and Systemic Therapies during Cancer Treatment and Survivorship

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Jasmine I. Kashkoush,
  • Claire S. Burton,
  • Kai B. Dallas,
  • Humberto G. Villarreal,
  • Stephanie Jensen,
  • Seth A. Cohen

摘要

Purpose of review

The goal of this review is to consolidate the current understanding of cancer treatment-related bladder dysfunction and lower urinary tract symptoms.

Recent findings

Many cancer treatments are associated with irritative lower urinary tract symptoms. Chemotherapies can result in a hemorrhagic cystitis that can be difficult to manage. Common therapies for hemorrhagic cystitis include hyperbaric oxygen therapy, clot evacuation, fulguration, and intravesical instillation of astringent agents. Among breast cancer patients, some of those managed with endocrine therapies, such as selective estrogen receptor modulators and aromatase inhibitors, develop irritative voiding symptoms secondary to decreased estrogen stores. Immunotherapy-related adverse events regarding the bladder are rare and have only been described in case reports. These commonly include dysuria, hematuria, and urinary frequency. Lastly, in the setting of non-muscle invasive bladder cancer, intravesical therapies have been utilized in intermediate and high-risk disease. These intravesical therapies cause irritative urinary symptoms such as urgency, frequency, dysuria, and even urge incontinence. These side effects can lead to poor compliance which can lead to progression of disease.

Summary

Systemic and local intravesical treatments each contribute to the development and persistence of bothersome symptoms such as urgency, frequency, dysuria, and hematuria. Further studies looking at the implications of systemic and intravesical therapy-related bladder dysfunction during treatment and cancer survivorship could assist with the counseling and management of patients’ expectations, informing therapy selection during a shared-decision making process.